What is known and objective: The CFTR potentiator, ivacaftor (IVA), has been widely used in the treatment of cystic fibrosis (CF) patients with the G551D mutation. To date, there has been limited information on the microbiological status of patients on this therapy and no data on the effect (if any) on the in vivo antibiotic susceptibility of Pseudomonas aeruginosa isolated from patients on therapy. Although IVA intervention is not designed per se as anti-infective, the effect (if any) of this molecule to CF patients' microbiological status merits careful monitoring. Therefore, it was the aim of this observational study to examine the effect in patients, both before and after commencement of IVA therapy, on several commonly reported microbiological markers in CF patients, including (i) bacterial density, (ii) frequency (rate) of isolation of bacterial pathogens, particularly P. aeruginosa, and (iii) antimicrobial susceptibility of these isolates to commonly prescribed oral and iv antibiotics. In addition, we wished to examine the requirements for these antibiotics in CF patients, before and after commencement of IVA therapy.
| WHAT IS KNOWN AND OBJECTIVE
The dominant feature of cystic fibrosis (CF)-related disease is the de- In microbiological terms, what is not well understood is the sequencing and interactions of these factors, when they occur together in a particular pattern, what precipitates the tipping of the relatively stable CF lung into a pulmonary exacerbation or alternatively the interactions which drive the CF lung to a more stable situation, thereby reducing infection and exacerbations. In addition, the relative contribution and interaction of the human host undoubtedly play a significant part in driving this stable equilibrium to a state of relative instability and hence onwards to a potential pulmonary exacerbation.
The 21st century is witnessing the development of many new pharmacological interventions in CF, in order to ameliorate the effects of CF transmembrane conductance regulator (CFTR) dysfunction and thus improve patient outcomes. One such intervention is the use of CFTR correctors/potentiators, as an effective intervention, which has revolutionized CF care in those patients with a genetic profile of their alleles which are predicted to benefit from such interventions. 
| MATERIALS AND METHODS

| Patient population
A retrospective analysis was conducted on 15 adult cystic fibrosis patients, who were receiving therapeutic treatment for their CF with oral ivacaftor. Each patient had a confirmed diagnosis of CF, with at least one copy of the G551D mutation. Patients had an age range of 16-43 years and there were nine males (age range: 16-43 years) and seven females (age range: 18-32 years). Male patients' treatment duration ranged from 18 to 30 months, with a mean treatment duration of 24 months and female patients' treatment durations ranged from 18 to 29 months, with a mean treatment duration of 23.4 months.
| Antibiotic treatment and microbiological parameters analysed
Each parameter was examined (i) 2 years prior to commencement of ivacaftor therapy and (ii) 2 years post-ivacaftor therapy.
Archived microbiological data were analysed from the patients' clinical microbiology record file, with particular reference to (i) total Additionally, the number of antibiotic courses, both oral and intravenous (IV), was analysed and expressed as the mean courses of antibiotics given per month over the 2 years prior to commencement of ivacaftor therapy and the 2 years after commencement of ivacaftor therapy.
| Statistical analysis
Student t tests were used to compare pre-ivacaftor and post-ivacaftor microbiology findings. Where unpaired t tests were employed, F values were calculated to determine equal or unequal variance. P values and confidence intervals (CIs) were two-sided, where P ≤ .05 (5%) was deemed significant. Error bars were calculated as ±standard error of the mean (SEM).
| RESULTS
| Antibiotic therapy
There was no significant difference between the number of oral antibi- All patients who were taking nebulized anti-pseudomonal antibiotics for suppressive therapy continued to take these after commencement of IVA therapy, and thus, there was no change in the rate of inhaled antibiotics with the Pseudomonas-positive patients.
| Rate & density of Pseudomonas aeruginosa
isolation from respiratory specimens
| Non-mucoid Pseudomonas aeruginosa
Eleven patients from the total 15 patients included in this study were culture-positive for NM-PA, prior to commencement of IVA therapy. 
Number of oral antibiotic courses per month
Patient number
No. of oral AB courses/month before IVA therapy
No. of oral AB courses/month after commencement of IVA therapy
Overall at a population level, there was no significant difference in either the rate (P = .90) or density (P = .07) of NM-PA, following commencement of IVA therapy (Table 1) . When examined statistically, at individual patient level, the density of NM-PA was significantly lower (before vs after commencement IVA therapy) in one patient (P = .02), even though this patient had a constant rate of NM-PA isolation ( Figure 3) . One patient acquired an NM-PA after commencement of IVA therapy, but this isolate appeared to be transient, as it was only reported in a single specimen, whereby the remaining six specimens were negative (data not shown). The other three patients remained NM-PA free.
| Mucoid Pseudomonas aeruginosa
Nine patients in this study were culture-positive for M-PA, prior to commencement of IVA therapy. Overall, at a population level, there was a significant lowering in both the rate (P = .02) and density (P = .006) of M-PA, following commencement of IVA therapy (Table 1 and Figure 4 ). Interestingly, a reduced density of M-PA isolation was statistically observed in three of the nine patients (33.3%) and additionally two patients became negative for M-PA after commencement of IVA therapy. None of the six patients previously negative for M-PA prior to IVA therapy gained M-PA, after commencement of therapy.
| Other microorganisms
There was no significant difference in both the rate (P = .37) and density (P = .43) of Staphylococcus aureus in patients (n = 7), before vs after commencement of IVA therapy. Additionally, in one patient, there was no significant difference in the rate or density of Burkholderia cenocepacia, before vs after commencement of IVA therapy. For other nonPseudomonas organisms, Table 2 details a qualitative comparison of microorganisms cultured in patients before and after commencement of IVA therapy.
| Antibiotic susceptibility in PA isolates
The RRI 3 was employed as a semiquantitative method to determine the susceptibility of NM-PA and M-PA. In total, 366 isolates of PA were analysed for antibiotic susceptibility against 11 antibiotics, including 220 NM-PA (n = 109 and n = 111 before and after commencement of IVA therapy, respectively), as well as 146 M-PA (n = 77 and n = 69 before and after commencement of IVA therapy, respectively). This For total PA, there is a significant increase in susceptibility relating to ceftazidime (P = .002), tazocin (P = .004), aztreonam (P = .045) and meropenem (P = .005). Regarding NM-PA, three β-lactams showed a significant increase in susceptibility, namely ceftazidime (P = .03), tazocin (P = .002) and meropenem (P = .02), whereas only ceftazidime showed a significant increase in susceptibility (P = .04), with M-PA (see Figure 5A -C).
| DISCUSSION
With any novel non-antimicrobial pharmacological intervention in CF, it is important to carefully monitor the microbiological status of patients on therapy, in order to ensure that the intervention is not having a deleterious effect on the patients' microbiological parameters, which could potentially manifest in clinical deterioration. In this observational study, our objective was to retrospectively examine the microbiology of CF patients, who had received IVA therapy. This was achieved by examining microbiological data routinely gathered as part of the patient CF care pathway, from 2 years proceeding initiation
F I G U R E 3 (A) Rate of non-mucoid
Pseudomonas aeruginosa (PA) isolation before and after commencement of ivacaftor (IVA) therapy in patients who were chronically colonized prior to the commencement of IVA therapy. (B) Density of non-mucoid PA isolation before and after commencement of IVA therapy in patients who were chronically colonized prior to the commencement of IVA therapy. When examined statistically, at individual patient level, the density of NM-PA was significantly lower (before vs after commencement IVA therapy) in 1 patient (P = .02), even though this patient had a constant rate of NM-PA isolation). One patient acquired an NM-PA after commencement of IVA therapy, but this isolate appeared to be transient, as it was only reported in a single respiratory specimen, whereby the remaining 6 specimens were negative (data not shown). The other 3 patients remained NM-PA free Similarly, in a recent study from the Czech Republic, a 21% reduction on antibiotic therapy (per patient-year) was reported (P < .001);
however, it is not clear whether this therapy included oral, iv or both.
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In our study, we observed an overall significant reduction (86.7%) in the number of iv antibiotic courses per month and a 20% reduction in the number of oral antibiotic courses per month, although not statistically significant.
The question does however remain from our study, as to why iv antibiotic usage went down, whereas oral usage remained unaltered.
One possible explanation is a lower clinical threshold for starting an oral antibiotic in healthier patients versus that for commencement of an iv antibiotic in sicker patients. Consequently, oral antibiotics may be an interesting first choice for examining antimicrobial stewardship within CF.
There was no significance difference in either the rate of isolation or density of NM-PA after commencement of IVA therapy. This was in contrast to M-PA, where there was a significant reduction in both the rate of isolation and density. To date, there have been no other reports which have divided total PA into NM-PA and M-PA components; however, the study by Heltshe et al. demonstrated that mucociliary clearance increased from 8.5% ± 1.7%
at baseline to 18.7% ± 2.3% and 17.7% ± 1.7% at 1 and 3 months post-treatment, respectively (P < .001 for each comparison to baseline). Dramatic improvements in peripheral lung clearance were also demonstrated (1.5% ± 1.8% vs 12.2% ± 2.0%, 9.1% ± 2.4% at baseline, 1 and 3 months, respectively; P < .05 for each comparison to baseline.
Current research, which is part of the GOAL observational study, from Sagel's group in Colorado, also presented at the recent NACFC meeting. 8 Induced sputum was collected pre-and post-ivacaftor treatment in 14 subjects (age 27 ± 14 years; FEV1 84% ± 23% pre- On first examination of the Sagel's data, 8 it would appear that nothing significant happened to the total bacterial counts nor the PA counts, which is counter-intuitive to data of Donaldson, The consequences of which modality is happening are profound. In the case of (i) above, bacterial cells are not actively dividing nor dying, and therefore, they will not have a high metabolic turnover and should not be as visible to the host immune system. However, in the case of (ii) above, although there does not appear to be much happening, in terms of changes in bacterial counts, there is an important occult metabolism taking place, which would be very visible to the host's immune system, which would drive inflammatory processes. Therefore, it is import to understand the microbiological mechanisms underpinning the fate of constant bacterial populations within the CF airways in patients on IVA.
To date, there have been no reports on the effect of IVA therapy on antibiotic susceptibility in PA. In our study, overall, there was no Importantly, antibiotic susceptibility from patients on IVA therapy is not reduced, and therefore, IVA therapy does not appear to have a detrimental association with antimicrobial therapy.
| WHAT IS NEW AND CONCLUSIONS
Overall, although the findings of this study cannot directly correlate with the effect of IVA therapy with microbiological parameters, it is of interest to note that microbiological parameters with patients on IVA therapy were not detrimentally affected. Indeed, overall, (i) the requirement for less iv antibiotic therapy, (ii) a reduction in the rate and density of M-PA and (iii) no reduction in antibiotic susceptibility suggest an improvement in the microbiology status of patients on IVA therapy.
